Q-omics provides the consensus-scored OR13J1 profile across patient tissues and cancer cell-line models. OR13J1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, OR13J1 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, OR13J1 RNA expression shows 10,417 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight DLBC, THCA, and SARC as cancer lineages where OR13J1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR13J1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR13J1 survival associations across molecular data types. OR13J1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR13J1 RNA expression–survival associations across cancer types. High OR13J1 expression shows unfavorable associations in DLBC, KIRP, THYM, BLCA and UCEC, but favorable associations in CESC. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for OR13J1 RNA expression.
This table summarizes OR13J1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for OR13J1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR13J1 shows lower tumor expression in PRAD and higher tumor expression in THCA, BRCA, KIRC, KICH and COAD. The THCA box plot shows higher OR13J1 RNA expression in tumor versus normal tissue (log2 FC = +0.095, t-test p < 0.001).
This table shows molecular features associated with OR13J1 in patient tissues and cancer cell lines. In patient samples, OR13J1 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set. In cancer cell lines, OR13J1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
